ストックスクリーナーアプリを入手
65.97
1.81%
0.93
Ptc Therapeutics Inc (PTCT) 最新ニュース
Assessing PTC Therapeutics (PTCT) Valuation After Encouraging New Huntington’s Disease Data - Yahoo Finance
Horizon Investments LLC Takes $3.06 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And Franchise Pressures - Yahoo Finance
PTC Therapeutics stock sinks as pivotal data fails to calm sellers - MSN
Three PTC investor conference webcasts start May 12 and stay up 30 days - Stock Titan
Vanguard Group Inc. Purchases 514,204 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
UBS Group AG Has $73.28 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Hussman Strategic Advisors Inc. Has $1.91 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results - Insider Monkey
Is PTC Therapeutics a Better Buy Than Eli Lilly? - Trefis
PTC Therapeutics Hits Day Low of $63.76 Amid Price Pressure - Markets Mojo
MSN Money - MSN
PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone - Yahoo Finance
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Vanguard holds 4.28M PTC Therapeutics (NASDAQ: PTCT) shares - Stock Titan
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday - MarketBeat
PTC Therapeutics Stock To $84? - Trefis
Is 12.3% Fall In PTC Therapeutics (PTCT) Stock A Buying Opportunity? - Trefis
PTC Therapeutics Drops 8.3% Amid Sector-Wide Selling - AlphaStreet
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's DiseaseSlideshow (NASDAQ:PTCT) 2026-04-29 - Seeking Alpha
Vanguard (NASDAQ: PTCT) holds 4.87M PTC Therapeutics shares - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.5%Here's What Happened - MarketBeat
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $93 - Moomoo
AA meeting of minds as PTC, Novartis push votoplam in HD - BioWorld News
Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance - simplywall.st
PTC Therapeutics, Inc. $PTCT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
M&T Bank Corp Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals - MarketBeat
PTCT: Promising Results in Huntington's Disease Treatment Study - GuruFocus
PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026 - marketscreener.com
PTC Therapeutics Reports Positive 24-Month Votoplam Data - TipRanks
PTC Therapeutics (NASDAQ: PTCT) shows 52% slowing in HD study - Stock Titan
PTC reports votoplam slowed Huntington’s disease progression by 52% - Investing.com Canada
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam - ChartMill
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study - ChartMill
Teachers Retirement System of The State of Kentucky Buys 19,000 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations | DelveInsight - Barchart.com
PTC Therapeutics Inc (PTCT) - MSN
Q3 2025 PTC Therapeutics Inc Earnings Call Transcript - GuruFocus
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics, Inc. $PTCT Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Assessing PTC Therapeutics (PTCT) Valuation After Recent Share Price Swings And Pipeline Progress - Sahm
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - MSN
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Nasdaq
PTC Therapeutics CEO Matthew Klein sells $202,093 in stock - Investing.com UK
PTC Therapeutics CEO Matthew Klein sells $202,093 in stock By Investing.com - Investing.com India
Matthew Klein Sells 2,850 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Automatic tax sale trims PTC Therapeutics (PTCT) CEO stake slightly - Stock Titan
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $75 - Moomoo
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):